NCT02412059 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Banerjee PJ, Woodcock MG, Bunce C, Scott R, Charteris DG
A pilot study of intraocular use of intensive anti-inflammatory; triamcinolone acetonide to prevent proliferative vitreoretinopathy in eyes undergoing vitreoretinal surgery for open globe trauma; the Adjuncts in Ocular Trauma (AOT) Trial: study protocol for a randomised controlled trial. Trials. 2013 Feb 13;14:42. doi: 10.1186/1745-6215-14-42.
Bu SC, Kuijer R, Li XR, Hooymans JM, Los LI
Idiopathic epiretinal membrane. Retina. 2014 Dec;34(12):2317-35. doi: 10.1097/IAE.0000000000000349. Review.
Gilbert C, Hiscott P, Unger W, Grierson I, McLeod D
Inflammation and the formation of epiretinal membranes. Eye (Lond). 1988;2 Suppl:S140-56. Review.
Grinnell F
Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994 Feb;124(4):401-4. Review.
Hiscott PS, Unger WG, Grierson I, McLeod D
The role of inflammation in the development of epiretinal membranes. Curr Eye Res. 1988 Sep;7(9):877-92.
Joshi M, Agrawal S, Christoforidis JB
Inflammatory mechanisms of idiopathic epiretinal membrane formation. Mediators Inflamm. 2013;2013:192582. doi: 10.1155/2013/192582. Epub 2013 Nov 11. Review.
Saran BR, Brucker AJ
Macular epiretinal membrane formation and treated retinal breaks. Am J Ophthalmol. 1995 Oct;120(4):480-5. Review. Erratum in: Am J Ophthalmol 1996 Mar;121(3):334.
Snead DR, James S, Snead MP
Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation. Eye (Lond). 2008 Oct;22(10):1310-7. doi: 10.1038/eye.2008.36. Epub 2008 Mar 14.
Tano Y, Sugita G, Abrams G, Machemer R
Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980 Jan;89(1):131-6.

Topical Use of Corticosteroid to Prevent Epiretinal Membrane Formation in Eyes With Retinal Tear Undergoing Laser Retinopexy: a Pilot Prospective Clinical Study

Details for clinical trial NCT02412059

Clinical trial NCT02412059 - References